- Home
- RGNX vs SIGA Comparison
RGNX vs SIGA Comparison
Compare RGNX & SIGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RGNX
- SIGA
- Stock Information
- Founded
- RGNX 2008
- SIGA 1995
- Country
- RGNX United States
- SIGA United States
- Employees
- RGNX N/A
- SIGA N/A
- Industry
- RGNX Biotechnology: Biological Products (No Diagnostic Substances)
- SIGA Biotechnology: Pharmaceutical Preparations
- Sector
- RGNX Health Care
- SIGA Health Care
- Exchange
- RGNX Nasdaq
- SIGA Nasdaq
- Market Cap
- RGNX 387.0M
- SIGA 422.9M
- IPO Year
- RGNX 2015
- SIGA 1997
- Fundamental
- Price
- RGNX $8.54
- SIGA $6.44
- Analyst Decision
- RGNX Strong Buy
- SIGA
- Analyst Count
- RGNX 8
- SIGA 0
- Target Price
- RGNX $31.75
- SIGA N/A
- AVG Volume (30 Days)
- RGNX 1.1M
- SIGA 386.9K
- Earning Date
- RGNX 07-31-2025
- SIGA 07-31-2025
- Dividend Yield
- RGNX N/A
- SIGA 9.32%
- EPS Growth
- RGNX N/A
- SIGA N/A
- EPS
- RGNX N/A
- SIGA 0.67
- Revenue
- RGNX $156,718,000.00
- SIGA $120,330,310.00
- Revenue This Year
- RGNX $327.08
- SIGA N/A
- Revenue Next Year
- RGNX N/A
- SIGA $95.31
- P/E Ratio
- RGNX N/A
- SIGA $9.60
- Revenue Growth
- RGNX 80.70
- SIGA N/A
- 52 Week Low
- RGNX $5.04
- SIGA $4.95
- 52 Week High
- RGNX $15.36
- SIGA $12.83
- Technical
- Relative Strength Index (RSI)
- RGNX 46.38
- SIGA 57.63
- Support Level
- RGNX $7.82
- SIGA $6.01
- Resistance Level
- RGNX $10.64
- SIGA $6.49
- Average True Range (ATR)
- RGNX 0.82
- SIGA 0.25
- MACD
- RGNX -0.19
- SIGA 0.00
- Stochastic Oscillator
- RGNX 25.57
- SIGA 75.32
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.
About SIGA SIGA Technologies Inc.
SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus. The company derives maximum revenue from United States.